Introduction
Thiazolium ring is one of the two heterocyclic fragments of thiamine (vitamin B1) which can exhibit coenzyme and non-coenzyme activity in living cells and is necessary for energy metabolism and nervous system functioning. [1] [2] [3] Severe deficiency of vitamin B1 leads to beriberi, Wernicke-Korsakoff syndrome, and can be one of the reasons of Alzheimer's and Parkinson's diseases. 4, 5 Thiamine, its derivatives and structural analogs may target specific and other proteins including mitochondrial enzymes which are involved in regulation of acetylcholine biosynthesis. 2, 6 It was reported that thiamine and thiamine-like compounds exhibit inhibitory properties against carbonic anhydrase isozymes. 7 NPhenacylthiazolium bromide and some other thiazolium compounds can cleave the crosslinks of AGEs (advanced glycation end products). 8 Mono-and bis-thiazolium salts were described as potential therapeutic agents for malaria. 9, 10 Acetylcholinesterase (AChE) catalyzes hydrolysis of acetylcholine playing a key role in termination of cholinergic neurotransmission. 11 Butyrylcholinesterase (BChE), which has 65% identity in amino acid sequence to AChE, is able to compensate the lack of AChE activity 12 and may be involved in formation of amyloid plaques. 13 Donepezil (Fig. 1) , pyridostigmine, galantamine, and rivastigmine as AChE inhibitors can be used for treatment of Alzheimer's disease, 14 myasthenia gravis, 15 and glaucoma. 16 They also showed beneficial effects in therapy of Lewy body dementias, 17 Parkinson's disease, 18 and schizophrenia. 19 Different classes of AChE and BChE inhibitors have been designed previously including 2,4-substituted thiazoles, [20] [21] thiazolotriazinones, 23 and benzothiazoles. 24 However, thiamine (compound 1, Fig. 1 ) and some thiazolium salts were reported to have only weak inhibitory effects on AChE. 25 Our interest in searching for effective inhibitors of both AChE and BChE has been focused on O-substituted structural analogues of thiamine (compounds 3, Fig. 1) . O-Benzoylthiamine 26 2 is known as a metabolite of benfotiamine, 27 the most widely used synthetic precursor of vitamin B1. We supposed that N-benzylthiazolium moiety of the compounds 3 can mimic the binding of N-benzylpiperidine part of donepezil to the active site of cholinesterase, and different acyl groups linked to the thiazolium ion were expected to exert influence of the inhibitors on the enzyme.
Here, we designed a series of O-substituted derivatives of 3-benzyl-5-(2-hydroxyethyl)-4-methyl-1,3-thiazolium chloride, among which some compounds were identified as potential inhibitors with selectivity for either AChE or BChE.
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Synthesis
O-Acyl-substituted thiazolium salts were prepared using known synthetic methods. On the first stage, 5-(2-hydroxyethyl)-4-methyl-1,3-thiazole was converted to the O-substituted derivatives by reaction with appropriate benzoyl or other acyl chlorides 28 in dichloromethane in the presence of triethylamine. Then, the O-substituted thiazoles were quaternized with corresponding benzyl chlorides in anhydrous acetonitrile giving thiazolium salts 3a-w (Scheme 1). All compounds were obtained in moderate to good yield. After crystallization of the crude products, the thiazolium salts were characterized by 1 H NMR, 13 C NMR and MS.
Structure and activity relationship
The compounds 3a-3w were tested in vitro as inhibitors of AChE from Electric еel and BChE from equine serum, which share significant similarity with the human enzymes. The activities of the enzymes were determined by a modified Ellman's method. 29 According to the obtained results (Table 1) , compounds 3a-3w exhibited inhibitory effects with IC50 values in the micromolar or nanomolar range depending on substituents at positions 3 and 5 of the thiazolium ring. The inhibiting potency of the Osubstituted derivatives of 3-benzyl-5-(2-hydroxyethyl)-4-methyl-1,3-thiazolium chloride was sufficiently increased as compared to corresponding O-substituted derivatives of thiamine. As an example, O-benzoyl-containing thiazolium salt 3a exhibited micromolar inhibitory activity for AChE with moderate selectivity over BChE, while O-benzoylthiamine 2 did not inhibit AChE and BChE at the concentration of 10 µМ. It should also be noted that N-benzylthiazolium-based compound 3a is more active inhibitor of AChE than corresponding N-phenacylthiazolium derivative. 30 The presence of more bulky O-adamantoyl or O-adamantylacetyl fragments instead of benzoyl one of compound 3a decreased the inhibition of AChE. 31 Compounds 3b-3d and 3g with 2-chloro, 4-chloro, 4-methoxy, 3,5-dichloro-4-ethoxy groups at the benzoyl moiety exhibited only slightly enhanced potency against AChE and BChE compared with unsubstituted O-benzoyl derivative 3a. Modification of the benzoyl fragment by 3-chloro and 4-methoxy groups gave compound 3f having IC50 value of 0.11 µM for AChE and displaying selectivity over BChE (IC50 = 1.9 µM). Introduction of 2-nitro, 3-nitro, 4-nitro, or 2-chloro-5-nitro groups in the benzoyl fragment (compounds 3h-3k) resulted in increasing AChE inhibition and improved selectivity over BChE. The AChE inhibitors 3i (IC50 = 0.056 µM) and 3j (IC50 = 0.096 µM) with significantly lower potency against BChE were selected to further study the relationship between the structure and activity. Unfortunately, smaller inhibitory effects on AChE and BChE were observed in case of compounds 3m-3o bearing 2-methylbenzyl, 3-methylbenzyl, or 4-methylbenzyl substituents in position 3 of the thiazolium ring. Comparison of compounds 3k and 3l, as well as 3j and 3p showed a slight increase in BChE inhibition by N-(2-chlorobenzyl)-substituted thiazolium salts. However, N-(4-chlorobenzyl) derivative 3q displayed a decreased capacity to inhibit both AChE and BChE. These results suggest that among the compounds synthesized in this study, N-benzyl-containing derivatives and their 2-chlorosubstituted analogs can provide the best inhibition of AChE. High inhibitory activities toward AChE were observed for 5-(2-chloro-5-nitrobenzoyloxyethyl) and 5-(4-morpholino-3-nitrobenzoyloxyethyl) substituted thiazolium salts 3l, 3s, and 3t, displaying IC50 values of 28 nM, 32 nM and 20 nM with approximately 35-fold, 90-fold and 45-fold selectivity over BChE, respectively. Under the assay conditions, the effects of these inhibitors are comparable with activity of donepezil, which showed IC50 values of 13 nM for AChE and 2.3 µM in case of BChE.
Replacing the 4-morpholino-3-nitrophenyl fragment by biphenyl-4-yl group resulted in much weaker inhibition of AChE, but showed some increased inhibition of BChE. A significant increment of inhibitory activity towards BChE was observed for compounds 3v and 3w containing diphenylmethylcarbonyloxyethyl substituent in position 5 of the thiazolium ring. These thiazolium salts were potent inhibitors of BChE with IC50 values of 59 nM and 16 nM, respectively, demonstrating about three orders of magnitude selectivity for the BChE over AChE. Dose-dependent curves for AChE and BChE inhibition by compounds 3s and 3w indicated no significant differences in the Hill slopes which were close to 1. The further kinetic experiments were carried out with different substrate concentrations. The double reciprocal Lineweaver-Burk plots ( Fig.  2) showed that compounds 3s and 3w act as mixed-type inhibitors. For the inhibition of AChE by compound 3s, the values of Ki and Ki' are 14 ± 1 nM and 53 ± 8 nM, respectively. Thus the inhibitor can compete with the substrate for binding to the enzyme active site. Besides binding to the free enzyme, a mixed type inhibitor of AChE is supposed to interact with acyl-enzyme intermediate, which results in blocking the deacetylation step of acetylcholine hydrolysis. 32 For compound 3w which exhibits potent inhibition of BChE, the calculated values of Ki and Ki' are of 17 ± 2 nM and 31 ± 4 nM, respectively. The concentrations of inhibitor 3w were 7 nM, 14 nM, and 28 nM Molecular docking modeling was performed to understand the possible binding modes of compounds 3s and 3w in complexes with AChE and BChE. Compound 3s was docked into the active site region of human AChE (PDB code 4EY7 33 ). Before the simulation, molecules of water, ligands and the B chain were removed from the enzyme crystal structure. According to obtained model (Fig.  3) , benzyl fragment of the inhibitor 3s is involved in aromatic-aromatic interaction with Trp86 at the anionic subsite of catalytic site, and thiazolium ring shows such interaction with phenyl ring of Tyr341. 4-Morpholino-3-nitrobenzoyloxyethyl fragment is oriented towards peripheral anionic site, and its carbonyl oxygen participates in hydrogen bond formation with NH-group of backbone chain of Phe295, whereas phenyl ring of this substituent is involved in interaction with Val294 The differences between the inhibition profiles of AChE and BChE can be explained by structural features of these enzymes. The catalytic sites of both AChE and BChE are located at the bottom of the gorge on the depth of about 20 Å. 34 Several aromatic amino acid residues of AChE active site are represented by aliphatic ones in the structure of BChE. In addition, Tyr72, Tyr124, and Trp286 of the AChE peripheral anionic site are represented by Asn68, Gln119 and Ala277 in case of BChE. This provides BChE with a larger active site and free access for more bulky inhibitors. 35 Compound 3w was docked to the active site of human BChE (PDB code 4BDS 36 ). The inhibitor is located at the bottom of the gorge occupying the catalytic anionic site (Fig. 3) . 2-Chlorophenyl fragment of substituent in position 3 showed weak aromatic-aromatic interactions with the indole part of Trp82. The aromatic rings of bulky substituent in position 5 of the thiazolium ion are located near the Trp82 residue. The diphenylmethyl fragment participates in hydrophobic, van der Waals, and electrostatic interactions with Gly78, Glu197, Ala328, Trp430, Met437, His438, Gly439, and Tyr440, which contributes to stabilization of the enzyme-inhibitor complex.
Conclusions
This study demonstrated potential of O-substituted derivatives of 3-benzyl-5-(2-hydroxyethyl)-4-methyl-1,3-thiazolium chloride as potent and selective inhibitors of AChE and BChE. Inhibitory effects of the thiazolium-based compounds on the cholinesterases were found to depend on substituents at positions 3 and 5 of the thiazolium ring. Among the tested compounds, N-benzylthiazolium salt 3s bearing 4-morpholino-3-nitrobenzoyl substituent at position 5 showed IC50 value for inhibition of AChE in nanomolar range with approximately two orders of magnitude selectivity over BChE. At the same time, compound 3w containing 2,2-diphenylacetyl fragment demonstrated strong inhibitory effect on BChE and three orders of magnitude selectivity over AChE. The mixed type of inhibition suggests that the inhibitors may compete with the substrate for binding to the enzyme active site. Results of molecular docking indicate that the efficient coordination of thiazolium ring and substituents at position 3 and 5 can be responsible for activity and high selectivity of the inhibitors. The obtained data create a background for further designing cholinesterase inhibitors based on structural analogs of vitamin B1.
Experimental
Instruments and Reagents
1 H (500 MHz) and 13 C (125 MHz) NMR spectra were recorded on Bruker Avance DRX 500 spectrometer with TMS as an internal standard. The IR spectra were measured with a Vertex 70 spectrometer from KBr pellets. Melting points were measured with a Buchi melting point apparatus and are uncorrected. LC-MS spectra were obtained using an HPLC apparatus, Agilent 1100 Series, equipped with the diode-matrix and mass-selective detector Agilent LC/MSD SL. Spectrophotometric measurements were carried out with a Specord 210 Plus spectrophotometer.
Acetylcholinesterase from Electric eel (Type V-S, lyophilized powder, 200 units/mg protein) and butyrylcholinesterase from equine serum (lyophilized powder, ≥10 units/mg protein) were purchased from Sigma-Aldrich.
Synthetic procedure for compounds 3a-3w
To a solution of 1.44 g (10 mmol) 2-(4-methyl-1,3-thiazol-5-yl)ethanol and 1.7 ml (12 mmol) of triethylamine in 20 ml of dry dichloromethane was added dropwise a solution of 11 mmol corresponding aroyl or other acyl chloride in 10 ml of dichloromethane at 0-5 o C. The mixture was mixed overnight, then 50 ml of water was added, organic layer was separated, dried with anhydrous Na2SO4, and solvent evaporated under vacuum. The obtained esters were used without purification for further synthesis. To a solution of 10 mmol of ester in anhydrous acetonitrile was added 15 mmol of benzyl chloride or its derivatives, and the reaction mixture was refluxed for 20 h. Then the solvent was evaporated under vacuum, the residue was treated with hot acetone, and precipitate was filtered and recrystallized from methanol-acetone-diethyl ether mixture to give corresponding thiazolium salts. 5-(Chloromethyl)-2-methylpyrimidin-4-amine hydrochloride was used for quaternization of the Obenzoyl derivative of 2-(4-methyl-1,3-thiazol-5-yl)ethanol to obtain compound 2.
5-[2-(Benzoyloxy)ethyl]-3-benzyl-4-methyl-1,3-thiazolium chloride (3a)
Yield 56%, a light gray solid. Mp = 156-158 °C. 1 10.31 (s, 1H). 13 C NMR (125 MHz, DMSO-d6), δ: 12.1, 26.4, 56.2, 56.5, 64.0, 114.7, 122.0, 128.4, 129.4, 129.8, 131.9, 133.6,  135.6, 143.4, 158.4, 163.9, 165.7. IR (KBr), ν, cm -1 : 705, 1112, 1156, 1252, 1273, 1599 7.29-7.34 (m, 3H), 7.36-7.44 (m, 3H), 7.79-7.85 (m, 3H), 8.05-8.07 (m, 1H), 10.45 (s, 1H). 13 C NMR (125 MHz, DMSO-d6), δ: 12.0, 25.9, 56.3, 65.6, 124.7, 126.2, 128.4, 128.5, 129.3, 129.6, 129.7, 130.4, 133.5, 133.7, 134.3, 135.0, 143.5, 148.3 10.53 (s, 1H). 13 C NMR (125 MHz, DMSO-d6), 7.74-7.75 (m, 2H), 7.80-7.82 (m, 2H), 7.97-7.99 (m, 2H), 10.41 (s, 1H) . 13 C NMR (125 MHz, DMSOd6), δ: 12.0, 26.3, 56.3, 64.3, 127.5, 127.5 128.3, 128.5, 129.0, 129.3, 129.7, 130.3, 133.5, 135.4, 139.2 
AChE and BChE inhibition assays
The tested compounds 3a-3w were dissolved in DMSO and then were diluted with water to the required concentration. The solution, which consisted of 0.1 mM S-acetylthiocholine iodide, inhibitor, 25 mM phosphate buffer (pH 7.48), and 1% DMSO, was thermostated for 5 min at 25 o C. Then 10 μL of 50 mM ethanolic solution of DTNB was added for detection of AChE activity. 29 The reaction was started by adding the enzyme solution. The final assay volume was 0.5 mL. The activity of AChE was studied spectrophotometrically by measuring the absorbance of 5-thio-2-nitrobenzoate at 412 nm using molar extinction coefficient of 5-thio-2-nitrobenzoate of 14150 M -1 cm -1 . 37 The inhibition of BChE was studied under the same conditions with 0.5 mM S-butyrylthiocholine iodide as a substrate. The obtained Km values were of 0.20 mM and 0.26 mM for AChE and BChE, respectively. The IC50 values represent the concentrations of compounds which reduces enzyme activity by 50 %.
Molecular docking
The PDB crystal files of human AChE (PDB code 4EY7 33 ) and human BChE (PDB code 4BDS 36 ) were obtained from RCSB PDB (www.rcsb.org). 38 Before the docking calculations, ligands and water molecules were removed from the crystal structures. Molecular structures of compounds 3s and 3w were drawn in MarvinSketch and optimized by AM1 semi-empirical quantum mechanical method in program MOPAC. 39 Docking files were prepared using the MGLTools 1.5. 6 . The Autodock 4.2 program was employed to perform the calculations with using the Lamarckian genetic algorithm (LGA) method. 40 The program Discovery Studio 3.5 (Accelrys, San Diego, CA) was applied for analysis of inhibitor binding modes.
